Opus Genetics, Inc. (IRD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Opus Genetics, Inc. (IRD) has a cash flow conversion efficiency ratio of -0.641x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.83 Million) by net assets ($15.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Opus Genetics, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Opus Genetics, Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Opus Genetics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Opus Genetics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Opus Genetics, Inc. ranked by their cash flow conversion efficiency. Explore IRD operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NACL Industries Limited
NSE:NACLIND
|
-0.131x |
|
China Datang Corporation Renewable Power Co. Limited
STU:DT7
|
0.046x |
|
Grand Korea Leisure Co. Ltd
KO:114090
|
0.076x |
|
Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares
NASDAQ:ANSC
|
0.006x |
|
Mirrabooka Investments Ltd
AU:MIR
|
0.011x |
|
Anzheng Fashion
SHG:603839
|
-0.031x |
|
Symtek Automation Asia Co Ltd
TW:6438
|
0.039x |
|
Hanil Cement Co Ltd
KO:003300
|
0.022x |
Annual Cash Flow Conversion Efficiency for Opus Genetics, Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of Opus Genetics, Inc. from 2019 to 2025. View IRD live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.35 Million | $-35.25 Million | -2.297x | +39.61% |
| 2024-12-31 | $6.72 Million | $-25.58 Million | -3.804x | -16970.76% |
| 2023-12-31 | $49.91 Million | $-1.11 Million | -0.022x | -107.20% |
| 2022-12-31 | $46.24 Million | $14.31 Million | 0.310x | +135.51% |
| 2021-12-31 | $22.22 Million | $-19.37 Million | -0.872x | -272.70% |
| 2020-12-31 | $-13.47 Million | $-6.80 Million | 0.505x | +6.20% |
| 2019-12-31 | $-7.56 Million | $-3.59 Million | 0.475x | -- |
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 t… Read more